NO313999B1 - Strukturelt gen for pnumokokkisk protein - Google Patents
Strukturelt gen for pnumokokkisk proteinInfo
- Publication number
- NO313999B1 NO313999B1 NO19932890A NO932890A NO313999B1 NO 313999 B1 NO313999 B1 NO 313999B1 NO 19932890 A NO19932890 A NO 19932890A NO 932890 A NO932890 A NO 932890A NO 313999 B1 NO313999 B1 NO 313999B1
- Authority
- NO
- Norway
- Prior art keywords
- pspa
- protein
- region
- gene
- strain
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 84
- 102000004169 proteins and genes Human genes 0.000 title claims description 62
- 108010040473 pneumococcal surface protein A Proteins 0.000 claims abstract description 149
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 239000000523 sample Substances 0.000 claims abstract description 8
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 6
- 102000039446 nucleic acids Human genes 0.000 claims abstract 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract 4
- 101710138270 PspA protein Proteins 0.000 claims description 63
- 102000037865 fusion proteins Human genes 0.000 claims description 38
- 108020001507 fusion proteins Proteins 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 37
- 101150080370 pspA gene Proteins 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 23
- 241000588724 Escherichia coli Species 0.000 claims description 21
- 230000002480 immunoprotective effect Effects 0.000 claims description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 15
- 238000004873 anchoring Methods 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 208000035109 Pneumococcal Infections Diseases 0.000 claims description 13
- 102000053602 DNA Human genes 0.000 claims description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 210000001322 periplasm Anatomy 0.000 claims description 10
- 102000009016 Cholera Toxin Human genes 0.000 claims description 9
- 108010049048 Cholera Toxin Proteins 0.000 claims description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000002703 mutagenesis Methods 0.000 claims description 8
- 231100000350 mutagenesis Toxicity 0.000 claims description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 108091036078 conserved sequence Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 101150087320 ctxB gene Proteins 0.000 claims description 4
- 210000004897 n-terminal region Anatomy 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 239000003298 DNA probe Substances 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 230000003252 repetitive effect Effects 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 101001017904 Homo sapiens U6 snRNA-associated Sm-like protein LSm2 Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 102100033309 U6 snRNA-associated Sm-like protein LSm2 Human genes 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 108020001019 DNA Primers Proteins 0.000 claims 2
- 108020003215 DNA Probes Proteins 0.000 claims 2
- 239000003155 DNA primer Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 101001017896 Homo sapiens U6 snRNA-associated Sm-like protein LSm1 Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 102100033314 U6 snRNA-associated Sm-like protein LSm1 Human genes 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000013615 primer Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 30
- 239000012634 fragment Substances 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 9
- 235000013930 proline Nutrition 0.000 description 9
- 230000004224 protection Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- -1 lysine Chemical class 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710160102 Outer membrane protein B Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000680505 Streptococcus pneumoniae WU2 Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- MATBMWGLNMBFBE-UHFFFAOYSA-N [F].[Cr] Chemical compound [F].[Cr] MATBMWGLNMBFBE-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65677391A | 1991-02-15 | 1991-02-15 | |
| PCT/US1992/000857 WO1992014488A1 (en) | 1991-02-15 | 1992-02-12 | Structural gene of pneumococcal protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO932890D0 NO932890D0 (no) | 1993-08-13 |
| NO932890L NO932890L (no) | 1993-10-14 |
| NO313999B1 true NO313999B1 (no) | 2003-01-13 |
Family
ID=24634503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19932890A NO313999B1 (no) | 1991-02-15 | 1993-08-13 | Strukturelt gen for pnumokokkisk protein |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5728387A (de) |
| EP (2) | EP0786521A1 (de) |
| JP (3) | JP3215109B2 (de) |
| AT (1) | ATE168132T1 (de) |
| AU (1) | AU692678C (de) |
| CA (1) | CA2104014C (de) |
| DE (1) | DE69226167T2 (de) |
| DK (1) | DK0571538T5 (de) |
| ES (1) | ES2118812T3 (de) |
| FI (1) | FI933580A (de) |
| HK (1) | HK1013629A1 (de) |
| IE (2) | IE920479A1 (de) |
| IL (1) | IL100946A0 (de) |
| NO (1) | NO313999B1 (de) |
| WO (1) | WO1992014488A1 (de) |
| ZA (1) | ZA921025B (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965141A (en) * | 1991-02-15 | 1999-10-12 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein a |
| US6232116B1 (en) | 1991-02-15 | 2001-05-15 | University Of Alabama At Birmingham Research Foundation | Oral administration of pneumococcal antigens |
| US6231870B1 (en) * | 1995-06-02 | 2001-05-15 | Uab Research Foundation | Oral administration of pneumoccal antigens |
| US6592876B1 (en) * | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
| US6027734A (en) * | 1991-02-15 | 2000-02-22 | Uab Research Foundation | Mucosal administration of pneumococcal antigens |
| US5980909A (en) * | 1991-02-15 | 1999-11-09 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein A |
| CA2116261A1 (en) * | 1993-04-20 | 1994-10-21 | David E. Briles | Epitopic regions of pneumococcal surface protein a |
| US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
| AU734488B2 (en) * | 1994-05-20 | 2001-06-14 | Uab Research Foundation | Mucosal administration of pneumococcal antigens |
| US20020055101A1 (en) | 1995-09-11 | 2002-05-09 | Michel G. Bergeron | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| US6001564A (en) * | 1994-09-12 | 1999-12-14 | Infectio Diagnostic, Inc. | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| US6004802A (en) * | 1995-06-02 | 1999-12-21 | University Of Alabama At Birmingham | Oral administration of pneumococcal antigens |
| WO1996039113A2 (en) * | 1995-06-02 | 1996-12-12 | Uab Research Foundation | Oral administration of pneumococcal antigens |
| US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| ZA964896B (en) | 1995-06-07 | 1997-01-08 | Connaught Lab | Expression of lipoproteins |
| IL118578A (en) * | 1995-06-07 | 2006-12-31 | Connaught Lab | Hybrid nucleic acid molecule for expression of lipoproteins |
| HUP0600442A3 (en) * | 1995-06-07 | 2007-03-28 | Biochem Vaccines Inc | Streptococcal heat shock proteins members of the hsp70 family |
| US5994066A (en) * | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| US7078042B2 (en) | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| US5949537A (en) | 1996-04-18 | 1999-09-07 | American Air Liquide Inc. | In-line cell for absorption spectroscopy |
| US6165989A (en) | 1996-05-14 | 2000-12-26 | Smithkline Beecham Corporation | Era of Streptococcus pneumoniae |
| AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
| US5928895A (en) * | 1996-09-24 | 1999-07-27 | Smithkline Beecham Corporation | IgA Fc binding protein |
| US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
| US20030049636A1 (en) | 1999-05-03 | 2003-03-13 | Bergeron Michel G. | Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories |
| US20100267012A1 (en) | 1997-11-04 | 2010-10-21 | Bergeron Michel G | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
| IL130291A0 (en) * | 1996-12-04 | 2000-06-01 | Univ Alabama | Compositions and methods for administering pneumococcal DNA |
| KR19980067137A (ko) * | 1997-01-31 | 1998-10-15 | 박원훈 | 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신 |
| WO1999014333A2 (en) * | 1997-09-18 | 1999-03-25 | Pasteur Merieux Connaught | Improved method of production of pneumococcal surface proteins |
| US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
| US20010016200A1 (en) * | 1998-04-23 | 2001-08-23 | Briles David E. | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| EP1246935B1 (de) | 1999-09-28 | 2013-08-14 | Geneohm Sciences Canada Inc. | Konservierte gene und dessen benutzung für die herstellung von sonden und primern für mikroorganismen nachweis |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| AT410412B (de) | 2000-11-10 | 2003-04-25 | Inteco Int Techn Beratung | Verfahren zum elektroschlacke umschmelzen von metallen |
| US8691243B2 (en) | 2002-04-02 | 2014-04-08 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based Streptococcus pneumoniae vaccine |
| EP2275128B1 (de) * | 2002-04-02 | 2013-10-16 | Ben Gurion University Of The Negev Research And Development Authority | Streptococcus-pneumoniae-Vakzine auf Proteinbasis |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| AR058707A1 (es) | 2005-12-22 | 2008-02-20 | Glaxosmithkline Biolog Sa | Vacuna, procedimiento para fabricarla y su uso |
| BRPI0707154B8 (pt) | 2006-01-17 | 2022-12-20 | Forsgren Arne | composição de vacina |
| EA200901578A1 (ru) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| WO2009127676A1 (en) | 2008-04-16 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Vaccine |
| JP5721620B2 (ja) | 2008-05-02 | 2015-05-20 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | 免疫応答を刺激するための作製物および方法 |
| EP2545071A2 (de) | 2010-03-09 | 2013-01-16 | Maksyutov, Amir | Polyepitopkonstrukte sowie verfahren zu ihrer herstellung und verwendung |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| AU2011252850B2 (en) | 2010-05-14 | 2016-03-17 | Baxalta GmbH | OspA chimeras and use thereof in vaccines |
| US9109007B2 (en) | 2010-08-18 | 2015-08-18 | Purdue Pharma L.P. | MHC-I restricted epitopes containing non-natural amino acid residues |
| AR086405A1 (es) | 2011-05-17 | 2013-12-11 | Glaxosmithkline Biolog Sa | Vacuna de streptococcus pneumoniae |
| EP2877206B1 (de) | 2012-07-27 | 2019-11-27 | Baxalta GmbH | Zusammensetzungen mit chimären ospa-molekülen und verfahren zu ihrer verwendung |
| CN109289045A (zh) | 2012-09-19 | 2019-02-01 | 国立大学法人大阪大学 | 含有肺炎球菌表面蛋白a的肺炎球菌疫苗 |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| CA3044112A1 (en) * | 2016-12-03 | 2018-06-07 | The Uab Research Foundation | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN110499375B (zh) * | 2019-08-28 | 2023-03-28 | 首钢医院有限公司 | 结合多交叉置换扩增和金纳米检测肺炎链球菌的方法 |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
-
1992
- 1992-02-12 EP EP96119668A patent/EP0786521A1/de not_active Ceased
- 1992-02-12 CA CA002104014A patent/CA2104014C/en not_active Expired - Fee Related
- 1992-02-12 AT AT92907062T patent/ATE168132T1/de not_active IP Right Cessation
- 1992-02-12 EP EP92907062A patent/EP0571538B1/de not_active Expired - Lifetime
- 1992-02-12 WO PCT/US1992/000857 patent/WO1992014488A1/en active IP Right Grant
- 1992-02-12 DE DE69226167T patent/DE69226167T2/de not_active Expired - Fee Related
- 1992-02-12 ES ES92907062T patent/ES2118812T3/es not_active Expired - Lifetime
- 1992-02-12 DK DK92907062T patent/DK0571538T5/da active
- 1992-02-12 ZA ZA921025A patent/ZA921025B/xx unknown
- 1992-02-12 JP JP50675592A patent/JP3215109B2/ja not_active Expired - Fee Related
- 1992-02-14 IE IE047992A patent/IE920479A1/en not_active IP Right Cessation
- 1992-02-14 IL IL100946A patent/IL100946A0/xx unknown
- 1992-02-14 IE IE20000062A patent/IE20000062A1/en not_active IP Right Cessation
-
1993
- 1993-08-13 NO NO19932890A patent/NO313999B1/no not_active IP Right Cessation
- 1993-08-13 FI FI933580A patent/FI933580A/fi not_active Application Discontinuation
-
1994
- 1994-03-17 US US08/214,164 patent/US5728387A/en not_active Expired - Lifetime
-
1996
- 1996-03-08 AU AU47980/96A patent/AU692678C/en not_active Ceased
- 1996-07-02 JP JP8172110A patent/JPH09224680A/ja active Pending
-
1998
- 1998-12-23 HK HK98115032A patent/HK1013629A1/xx not_active IP Right Cessation
-
2000
- 2000-12-18 JP JP2000383712A patent/JP2001204482A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0571538A1 (de) | 1993-12-01 |
| WO1992014488A1 (en) | 1992-09-03 |
| JP3215109B2 (ja) | 2001-10-02 |
| EP0571538B1 (de) | 1998-07-08 |
| CA2104014C (en) | 2000-05-02 |
| AU692678C (en) | 2002-08-29 |
| DE69226167D1 (de) | 1998-08-13 |
| AU692678B2 (en) | 1998-06-11 |
| EP0571538A4 (en) | 1994-08-24 |
| FI933580A0 (fi) | 1993-08-13 |
| NO932890D0 (no) | 1993-08-13 |
| AU4798096A (en) | 1996-06-27 |
| AU1445392A (en) | 1992-09-15 |
| JPH06504446A (ja) | 1994-05-26 |
| IE920479A1 (en) | 1992-08-26 |
| IL100946A0 (en) | 1992-11-15 |
| HK1013629A1 (en) | 1999-11-26 |
| IE20000062A1 (en) | 2000-12-13 |
| EP0786521A1 (de) | 1997-07-30 |
| ES2118812T3 (es) | 1998-10-01 |
| US5728387A (en) | 1998-03-17 |
| DK0571538T3 (da) | 1999-04-19 |
| JP2001204482A (ja) | 2001-07-31 |
| JPH09224680A (ja) | 1997-09-02 |
| DE69226167T2 (de) | 1998-11-12 |
| FI933580A (fi) | 1993-10-13 |
| ATE168132T1 (de) | 1998-07-15 |
| DK0571538T5 (da) | 2002-03-04 |
| CA2104014A1 (en) | 1992-08-16 |
| ZA921025B (en) | 1992-11-25 |
| NO932890L (no) | 1993-10-14 |
| AU667668B2 (en) | 1996-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5476929A (en) | Structural gene of pneumococcal protein | |
| EP0571538B1 (de) | Strukturgen von pneumokokken-protein | |
| Scott et al. | Conversion of an M-group A streptococcus to M+ by transfer of a plasmid containing an M6 gene. | |
| US6326350B1 (en) | Transferrin receptor subunit proteins of Neisseria meningitidis | |
| Talkington et al. | A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence | |
| US5843444A (en) | Conjugate vaccine for group B streptococcus | |
| EA006232B1 (ru) | Стрептококковые антигены | |
| JP3245298B2 (ja) | 肺炎球菌表面プロテインａのエピトープ領域 | |
| EP0695803A2 (de) | Epitopische Regionen des Pneumokokken Oberflächen-Proteins A | |
| AU689452B2 (en) | Conjugate vaccine against group B streptococcus | |
| EP0500736B1 (de) | Rekombinanter impfstoff gegen schweinepleuropneumonie | |
| US5679768A (en) | Epitopic regions of pneumococcal surface protein A | |
| US6027734A (en) | Mucosal administration of pneumococcal antigens | |
| Kolberg et al. | Monoclonal antibodies that recognize a common pneumococcal protein with similarities to streptococcal group A surface glyceraldehyde-3-phosphate dehydrogenase | |
| AU667668C (en) | Structural gene of pneumococcal protein | |
| Miller et al. | Conservation of protective and nonprotective epitopes in M proteins of group A streptococci | |
| PT100193A (pt) | Gene estrutural de proteina pneumococica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |